» Articles » PMID: 34093138

Dopamine Neurons That Cotransmit Glutamate, From Synapses to Circuits to Behavior

Overview
Date 2021 Jun 7
PMID 34093138
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Discovered just over 20 years ago, dopamine neurons have the ability to cotransmit both dopamine and glutamate. Yet, the functional roles of dopamine neuron glutamate cotransmission and their implications for therapeutic use are just emerging. This review article encompasses the current body of evidence investigating the functions of dopamine neurons of the ventral midbrain that cotransmit glutamate. Since its discovery in dopamine neuron cultures, further work confirmed dopamine neuron glutamate cotransmission across species. From there, growing interest has led to research related to neural functioning including roles in synaptic signaling, development, and behavior. Functional connectome mapping reveals robust connections in multiple forebrain regions to various cell types, most notably to cholinergic interneurons in both the medial shell of the nucleus accumbens and the lateral dorsal striatum. Glutamate markers in dopamine neurons reach peak levels during embryonic development and increase in response to various toxins, suggesting dopamine neuron glutamate cotransmission may serve neuroprotective roles. Findings from behavioral analyses reveal prominent roles for dopamine neuron glutamate cotransmission in responses to psychostimulants, in positive valence and cognitive systems and for subtle roles in negative valence systems. Insight into dopamine neuron glutamate cotransmission informs the pathophysiology of neuropsychiatric disorders such as addiction, schizophrenia and Parkinson Disease, with therapeutic implications.

Citing Articles

The nucleus accumbens shell: a neural hub at the interface of homeostatic and hedonic feeding.

Marinescu A, Labouesse M Front Neurosci. 2024; 18:1437210.

PMID: 39139500 PMC: 11319282. DOI: 10.3389/fnins.2024.1437210.


Presynaptic sensor and silencer of peptidergic transmission reveal neuropeptides as primary transmitters in pontine fear circuit.

Kim D, Park S, Park S, Ye M, Chen J, Kang S Cell. 2024; 187(18):5102-5117.e16.

PMID: 39043179 PMC: 11380597. DOI: 10.1016/j.cell.2024.06.035.


Paradoxical Boosting of Weak and Strong Spatial Memories by Hippocampal Dopamine Uncaging.

Velazquez-Delgado C, Perez-Becerra J, Calderon V, Hernandez-Ortiz E, Bermudez-Rattoni F, Carrillo-Reid L eNeuro. 2024; 11(5).

PMID: 38755011 PMC: 11138129. DOI: 10.1523/ENEURO.0469-23.2024.


Modeling methamphetamine use disorder and relapse in animals: short- and long-term epigenetic, transcriptional., and biochemical consequences in the rat brain.

Elhadi K, Daiwile A, Cadet J Neurosci Biobehav Rev. 2024; 155:105440.

PMID: 38707245 PMC: 11068368. DOI: 10.1016/j.neubiorev.2023.105440.


Distributional coding of associative learning in discrete populations of midbrain dopamine neurons.

Avvisati R, Kaufmann A, Young C, Portlock G, Cancemi S, Costa R Cell Rep. 2024; 43(4):114080.

PMID: 38581677 PMC: 7616095. DOI: 10.1016/j.celrep.2024.114080.


References
1.
Root D, Wang H, Liu B, Barker D, Mod L, Szocsics P . Glutamate neurons are intermixed with midbrain dopamine neurons in nonhuman primates and humans. Sci Rep. 2016; 6:30615. PMC: 4967922. DOI: 10.1038/srep30615. View

2.
Yoshiki A, Moriwaki K . Mouse phenome research: implications of genetic background. ILAR J. 2006; 47(2):94-102. DOI: 10.1093/ilar.47.2.94. View

3.
Steinkellner T, Zell V, Farino Z, Sonders M, Villeneuve M, Freyberg R . Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons. J Clin Invest. 2018; 128(2):774-788. PMC: 5785252. DOI: 10.1172/JCI95795. View

4.
Straub C, Tritsch N, Hagan N, Gu C, Sabatini B . Multiphasic modulation of cholinergic interneurons by nigrostriatal afferents. J Neurosci. 2014; 34(25):8557-69. PMC: 4061393. DOI: 10.1523/JNEUROSCI.0589-14.2014. View

5.
Gaisler-Salomon I, Miller G, Chuhma N, Lee S, Zhang H, Ghoddoussi F . Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacology. 2009; 34(10):2305-22. PMC: 2811085. DOI: 10.1038/npp.2009.58. View